Phase 3 Trial of Masitinib in Slowing Progression Again Enrolling in US

Phase 3 Trial of Masitinib in Slowing Progression Again Enrolling in US

313015

Phase 3 Trial of Masitinib in Slowing Progression Again Enrolling in US

The U.S. Food and Drug Administration (FDA) has cleared AB Science to resume patient enrollment in its confirmatory Phase 3 trial investigating masitinib as an add-on treatment in people with amyotrophic lateral sclerosis (ALS). AB Science put a temporary hold on all its masitinib clinical trials due in June to investigate concerns of a greater risk of ischemic heart disease — a condition characterized by recurring chest pain and discomfort — with masitinib’s use. The FDA’s…

You must be logged in to read/download the full post.